About lazertinib
EGFR tyrosine kinase inhibitor
Used for
- Treats certain adults with advanced non-small cell lung cancer with EGFR mutations, with amivantamab.
Usual adult dose
240 mg by mouth once daily, with amivantamab, until disease progression or unacceptable side effects.
Common side effects
- Rash and acne-like skin changes
- Diarrhea
- Nail inflammation or infection
- Blood clots and bleeding
Important warnings
- Blood clots can be serious or fatal; monitoring and preventive treatment may be needed.
- Bleeding risk may increase, especially with blood-thinning medicines.
- Can cause lung inflammation; seek urgent assessment for new or worsening breathing symptoms.
- May harm an unborn baby; use effective contraception during treatment and for three weeks afterward.
Pregnancy
May cause fetal harm. Pregnancy testing and effective contraception are recommended during treatment and for three weeks after the last dose.
Breastfeeding
Do not breastfeed during treatment and for three weeks after the last dose.
Interactions
- Strong or moderate CYP3A4 inducers can lower lazertinib levels and reduce its effect.
- Avoid strong CYP3A4 inhibitors when possible; they can raise lazertinib levels.
- Lazertinib can increase levels of some P-glycoprotein or BCRP substrate medicines.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.